Matinas Non Operating Income Net Other from 2010 to 2026
| MTNB Stock | USD 0.59 0.02 3.28% |
Non Operating Income Net Other | First Reported 2015-03-31 | Previous Quarter 73 K | Current Value 99 K | Quarterly Volatility 623.7 K |
Check Matinas BioPharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Matinas BioPharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Selling General Administrative of 7.6 M or Other Operating Expenses of 17.7 M, as well as many indicators such as Price To Sales Ratio of 36.64, Dividend Yield of 2.79 or PTB Ratio of 0.36. Matinas financial statements analysis is a perfect complement when working with Matinas BioPharma Valuation or Volatility modules.
Matinas | Non Operating Income Net Other | Build AI portfolio with Matinas Stock |
Analyzing Matinas BioPharma's Non Operating Income Net Other over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Non Operating Income Net Other has evolved provides context for assessing Matinas BioPharma's current valuation and future prospects.
Latest Matinas BioPharma's Non Operating Income Net Other Growth Pattern
Below is the plot of the Non Operating Income Net Other of Matinas BioPharma Holdings over the last few years. It is Matinas BioPharma's Non Operating Income Net Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Matinas BioPharma's overall financial position and show how it may be relating to other accounts over time.
| Non Operating Income Net Other | 10 Years Trend |
|
Non Operating Income Net Other |
| Timeline |
Matinas Non Operating Income Net Other Regression Statistics
| Arithmetic Mean | 1,539,674 | |
| Geometric Mean | 631,022 | |
| Coefficient Of Variation | 106.27 | |
| Mean Deviation | 1,385,868 | |
| Median | 776,099 | |
| Standard Deviation | 1,636,207 | |
| Sample Variance | 2.7T | |
| Range | 4.3M | |
| R-Value | 0.89 | |
| Mean Square Error | 613.8B | |
| R-Squared | 0.79 | |
| Slope | 287,089 | |
| Total Sum of Squares | 42.8T |
Matinas Non Operating Income Net Other History
About Matinas BioPharma Financial Statements
Matinas BioPharma stakeholders use historical fundamental indicators, such as Matinas BioPharma's Non Operating Income Net Other, to determine how well the company is positioned to perform in the future. Although Matinas BioPharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Matinas BioPharma's assets and liabilities are reflected in the revenues and expenses on Matinas BioPharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Matinas BioPharma Holdings. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Operating Income Net Other | 4.1 M | 4.3 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Matinas BioPharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Matinas BioPharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Matinas Biopharma Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Matinas Biopharma Holdings Stock:Check out the analysis of Matinas BioPharma Correlation against competitors. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Matinas BioPharma. Expected growth trajectory for Matinas significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Matinas BioPharma assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Matinas BioPharma requires distinguishing between market price and book value, where the latter reflects Matinas's accounting equity. The concept of intrinsic value - what Matinas BioPharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Matinas BioPharma's price substantially above or below its fundamental value.
Understanding that Matinas BioPharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Matinas BioPharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Matinas BioPharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.